288 related articles for article (PubMed ID: 23507851)
21. A handheld fluorescence molecular tomography system for intraoperative optical imaging of tumor margins.
Zhao Q; Jiang H; Cao Z; Yang L; Mao H; Lipowska M
Med Phys; 2011 Nov; 38(11):5873-8. PubMed ID: 22047351
[TBL] [Abstract][Full Text] [Related]
22. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu targeted delivery of a nanoprobe enables dual photoacoustic and fluorescence tomography of ovarian cancer.
Xi L; Satpathy M; Zhao Q; Qian W; Yang L; Jiang H
Nanomedicine; 2014 Apr; 10(3):669-77. PubMed ID: 24269306
[TBL] [Abstract][Full Text] [Related]
24. Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy.
Chen Z; Xu P; Chen J; Chen H; Hu P; Chen X; Lin L; Huang Y; Zheng K; Zhou S; Li R; Chen S; Liu J; Xue J; Huang M
Acta Biomater; 2014 Oct; 10(10):4257-68. PubMed ID: 24969665
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
26. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
Baart VM; van der Horst G; Deken MM; Bhairosingh SS; Schomann T; Sier VQ; van der Mark MH; Iamele L; de Jonge H; Resnati M; Mazar AP; Pelger RCM; van der Pluijm G; Kuppen PJK; Vahrmeijer AL; Sier CFM
Eur J Cancer; 2021 Mar; 146():11-20. PubMed ID: 33561783
[TBL] [Abstract][Full Text] [Related]
27. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Lin R; Huang J; Wang L; Li Y; Lipowska M; Wu H; Yang J; Mao H
Biomater Sci; 2018 May; 6(6):1517-1525. PubMed ID: 29652061
[TBL] [Abstract][Full Text] [Related]
29. Optical molecular imaging-guided radiation therapy part 2: Integrated x-ray and fluorescence molecular tomography.
Shi J; Udayakumar TS; Wang Z; Dogan N; Pollack A; Yang Y
Med Phys; 2017 Sep; 44(9):4795-4803. PubMed ID: 28626876
[TBL] [Abstract][Full Text] [Related]
30. Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA.
Ciccocioppo R; Capri MG; Alberti S
J Histochem Cytochem; 1997 Sep; 45(9):1307-13. PubMed ID: 9283618
[TBL] [Abstract][Full Text] [Related]
31. Dendron-Grafted Polylysine-Based Dual-Modal Nanoprobe for Ultra-Early Diagnosis of Pancreatic Precancerosis via Targeting a Urokinase-Type Plasminogen Activator Receptor.
Li H; Wang P; Gong W; Wang Q; Zhou J; Zhu WH; Cheng Y
Adv Healthc Mater; 2018 Mar; 7(5):. PubMed ID: 29195018
[TBL] [Abstract][Full Text] [Related]
32. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
33. Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys.
Chen Y; Gong L; Gao N; Liao J; Sun J; Wang Y; Wang L; Zhu P; Fan Q; Wang YA; Zeng W; Mao H; Yang L; Gao F
Int J Nanomedicine; 2015; 10():6689-98. PubMed ID: 26604745
[TBL] [Abstract][Full Text] [Related]
34. Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.
Satpathy M; Wang L; Zielinski R; Qian W; Lipowska M; Capala J; Lee GY; Xu H; Wang YA; Mao H; Yang L
Small; 2014 Feb; 10(3):544-55. PubMed ID: 24038985
[TBL] [Abstract][Full Text] [Related]
35. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Juhl K; Christensen A; Persson M; Ploug M; Kjaer A
PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431
[TBL] [Abstract][Full Text] [Related]
36. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.
Baart VM; van Manen L; Bhairosingh SS; Vuijk FA; Iamele L; de Jonge H; Scotti C; Resnati M; Cordfunke RA; Kuppen PJK; Mazar AP; Burggraaf J; Vahrmeijer AL; Sier CFM
Mol Imaging Biol; 2023 Feb; 25(1):122-132. PubMed ID: 34642899
[TBL] [Abstract][Full Text] [Related]
37. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF
Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235
[TBL] [Abstract][Full Text] [Related]
38. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
39. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X
Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745
[TBL] [Abstract][Full Text] [Related]
40. Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo.
Kantamneni H; Barkund S; Donzanti M; Martin D; Zhao X; He S; Riman RE; Tan MC; Pierce MC; Roth CM; Ganapathy V; Moghe PV
BMC Cancer; 2020 Nov; 20(1):1082. PubMed ID: 33172421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
